Sermorelin Peptide: GHRH(1-29) Analogue, Mechanism, Benefits, and Research

Sermorelin is a synthetic peptide made of the first 29 amino acids of human growth hormone releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to release growth hormone (GH). Rather than supplying growth hormone directly, sermorelin stimulates the pituitary to produce and release its own, in pulses that remain subject to the body's normal feedback controls. Among the peptides used in hormone-optimization and longevity practice, sermorelin is unusual in having a genuine regulatory history: it was once an FDA-approved drug. This page covers what the sermorelin peptide is, how it works, what the published evidence supports, and where it stands with regulators today.

What Is Sermorelin?

Structure: GHRH(1-29)

Native GHRH is a 44-amino-acid peptide. Early structure–activity work showed that the full biological activity at the GHRH receptor resides in the first 29 residues. Sermorelin is that fragment — GHRH(1-29), with an amidated C-terminus — produced synthetically and typically supplied as sermorelin acetate.

Because it is the unmodified native sequence, sermorelin shares the native hormone's main weakness: it is rapidly broken down in circulation, chiefly by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids. Its circulating half-life is measured in minutes. That short exposure is the reason later analogues were engineered, and it is also why sermorelin produces a brief, physiological-looking GH pulse rather than a sustained elevation.

How Sermorelin Relates to Other GHRH Analogues

Sermorelin is the parent of a family of modified GHRH peptides. The detailed receptor physiology is covered on our GHRH peptides overview; the practical differences are summarized here.

The Regulatory History of Sermorelin

Geref: An FDA-Approved Growth Hormone Releasing Factor

Sermorelin acetate was approved by the FDA under the brand name Geref for the treatment of idiopathic growth hormone deficiency in children with growth failure, and a diagnostic form was used to assess pituitary GH reserve. Pediatric trials documented increases in growth velocity in children whose pituitary glands could still respond to GHRH stimulation — the population the drug was designed for.

Discontinuation

The manufacturer discontinued Geref in the United States in 2008. The discontinuation was not attributed to a safety finding. After Geref left the market, sermorelin became available to prescribers through compounding pharmacies rather than as a branded product.

Current Compounding Status

On our FDA peptide status tracker, sermorelin is listed in Category 1 — under evaluation, the interim category for bulk substances that may generally be used in 503A compounding while the FDA completes its review. "Under evaluation" is not a final determination, and categories can change. Check the tracker for current status before building a protocol around it.

How Sermorelin Works

Stimulating the Pituitary, Not Replacing the Hormone

Sermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP, which triggers both the release of stored growth hormone and the transcription of new GH. The released GH then acts on the liver and peripheral tissues, where it drives production of insulin-like growth factor 1 (IGF-1), the mediator of most of GH's anabolic effects.

Why Feedback Control Matters

The defining feature of sermorelin, compared with recombinant growth hormone, is that the body's regulatory loop stays intact:

• Somatostatin still suppresses GH release between pulses, so secretion remains pulsatile rather than continuous.
• Rising IGF-1 still feeds back to reduce GHRH-driven release, which limits how far GH and IGF-1 can be pushed.
• Pituitary capacity caps the response. Sermorelin can only amplify what the somatotrophs are able to produce.

This built-in ceiling is the main argument for GHRH-based therapy in adults who have a functioning pituitary but a declining GH output. It is also the main limitation: patients with pituitary damage or true organic GH deficiency may respond poorly, and sermorelin is not a substitute for replacement therapy in those patients.

Dependence on Pituitary Function

Because the effect runs through the pituitary, response varies with age, body composition, sleep, and metabolic state. Obesity and hyperinsulinemia blunt GH secretion generally, and they blunt the response to GHRH-class peptides as well. Measuring IGF-1 before and during therapy is how clinicians confirm whether a given patient is responding.

Sermorelin Benefits: What the Evidence Supports

The case for sermorelin benefits should be stated at the strength the evidence allows.

Established

• Pediatric growth. The approved indication — improving growth velocity in children with idiopathic GH deficiency who retain pituitary responsiveness — is supported by the trial data that led to Geref's approval.
• GH and IGF-1 stimulation. Across studies, sermorelin reliably increases GH secretion and, with repeated dosing, IGF-1, in people whose pituitaries can respond.

Studied, With Smaller or Less Consistent Evidence

• Older adults. Small controlled studies of GHRH(1-29) in healthy older adults, largely from the 1990s, reported increases in GH and IGF-1, and some reported modest changes in lean body mass and related measures. Results were not uniform across participants or studies, and the trials were short and small.
• Body composition and recovery. Effects on lean mass, fat mass, and recovery are plausible through the GH/IGF-1 axis and are widely reported in clinical practice, but controlled adult outcome data are limited.
• Sleep. GH secretion is closely coupled to slow-wave sleep, and GHRH signaling has been studied in sleep physiology. Improved sleep quality is a commonly reported effect; it is not a well-established clinical outcome.

Not Established

There are no large, long-term trials showing that sermorelin improves hard outcomes such as fracture rates, mortality, or functional independence in aging adults. Claims framed as "anti-aging" should be read in that light.

Sermorelin vs HGH

Recombinant human growth hormone (somatropin) delivers GH directly and bypasses the pituitary and its feedback controls. That makes it more potent and more predictable, and it also makes supraphysiological exposure easier to reach. Somatropin is an FDA-approved drug with specific approved indications, and U.S. law restricts distributing it for uses outside them.

Sermorelin works upstream, so its effect is smaller and self-limiting. We cover the comparison in detail — including how sermorelin compares with ipamorelin — in Sermorelin vs Ipamorelin (and HGH), and growth hormone itself on our HGH overview.

Patient Selection and Precautions

GHRH-class therapy is generally considered for adults with symptoms and laboratory findings consistent with a declining GH/IGF-1 axis and an intact pituitary. Points clinicians typically weigh:

• Active or recent malignancy. Because GH and IGF-1 promote cell growth, active cancer is a standard reason to avoid GH-axis stimulation.
• Pituitary or hypothalamic disease. Structural disease changes both the expected response and the appropriate workup.
• Glucose metabolism. GH opposes insulin action; baseline glycemic status and follow-up are relevant.
• Pregnancy and breastfeeding. Not an appropriate setting for sermorelin.
• Competitive athletes. GHRH and its analogues are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List.

Dosing, Side Effects, and Monitoring

This page is the overview. The specifics live on dedicated pages:

• Dosing frameworks — timing, frequency, titration against IGF-1, and treatment duration are covered in our sermorelin dosage guide.
• Side effects — injection-site reactions, flushing, headache, and GH-related effects are covered in sermorelin side effects.
• Reconstitution — sermorelin is supplied as a lyophilized powder; our peptide reconstitution calculator converts vial strength and diluent volume into syringe units.

IGF-1 is the standard monitoring marker. A baseline value, a follow-up after several weeks of therapy, and periodic checks thereafter let the prescriber confirm response and avoid pushing IGF-1 above the age-adjusted reference range.

Delivery Forms

Compounded sermorelin is most often prescribed as a lyophilized powder for subcutaneous injection. Some compounding pharmacies also prepare oral, sublingual, or nasal forms. A 29-amino-acid peptide is poorly absorbed across mucosal surfaces and is degraded in the gut, so these routes deliver a smaller and less predictable share of each nominal dose. They can suit patients who will not inject, but they are not dose-for-dose equivalents of injection, and response should still be confirmed with IGF-1.

Common Misconceptions About Sermorelin

• "Sermorelin is a natural HGH." It is not growth hormone. It is a fragment of the hormone that signals the pituitary to make growth hormone.
• "More is better." Because feedback limits the response, pushing the dose higher yields diminishing returns and more side effects. IGF-1, not dose, is the measure of effect.
• "It works for everyone." Response depends on pituitary capacity. Some patients show little IGF-1 change, which is itself useful diagnostic information.
• "It was banned." Geref was discontinued by its manufacturer, not withdrawn for safety.

Sermorelin in Practice

Sermorelin sits within a broader group of growth hormone peptides that includes GHRH analogues, ghrelin-receptor agonists such as ipamorelin, and the oral secretagogue MK-677. How these classes differ, and how they fit alongside training and nutrition, is covered in our hub on peptides for muscle growth.

Newtropin does not prescribe or compound. We connect licensed providers with a licensed 503A compounding partner. Prescribers evaluating sermorelin can start at For Providers.

This page is educational content for licensed healthcare professionals and is not medical advice.

Frequently Asked Questions

What is sermorelin?

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone, GHRH(1-29). It stimulates the pituitary gland to release its own growth hormone rather than supplying GH directly.

Is sermorelin FDA-approved?

Not currently as a marketed product. Sermorelin acetate was FDA-approved as Geref for pediatric growth hormone deficiency and was discontinued in the U.S. in 2008. It is now available through compounding, and our FDA tracker lists it in Category 1 (under evaluation).

What are the benefits of sermorelin?

The best-established effects are increased GH and IGF-1 secretion in people with a responsive pituitary, and improved growth velocity in the pediatric population it was approved for. Adult benefits such as changes in body composition, recovery, and sleep are studied and commonly reported but supported by smaller, shorter trials.

How is sermorelin different from HGH?

HGH replaces growth hormone directly and bypasses the body's feedback controls. Sermorelin stimulates the pituitary, so GH release stays pulsatile and self-limiting. The effect is smaller but closer to normal physiology.

Is sermorelin a peptide or a hormone?

Both descriptions apply. It is a peptide, a short chain of amino acids, and it is a fragment of a naturally occurring hormone, GHRH.

Is sermorelin banned in sports?

Yes. GHRH and its analogues, including sermorelin, are prohibited at all times under the WADA Prohibited List.